Non-alcoholic fatty liver disease (NAFLD)

NAFLD is currently the most common liver disorder both in the US and Europe. The fatty liver may progress to non-alcoholic steatohepatitis (NASH), which markedly increases the risk of cirrhosis and hepatocellular carcinoma. NAFLD is the hepatic manifestation of the metabolic syndrome and characterizes the majority of patients with type 2 diabetes. 

Objectives

1. To advance our understanding of the prevalence, diagnosis, pathogenesis, prevention and treatment of NAFLD.

2. To enable hepatologists and diabetologists and other specialists in cognate disciplines to interact.

EASD: Official endorsement

  • Approval of the Study group
  • Report of a new Study Group (Diabetologia)

Guidelines for the NAFLD Study Group

The NAFLD Study Group will follow the for ​Guidelines endorsed by the Executive Committee of the EASD (European Association for the Study of Diabetes) on 14 January 2013. 

Our Next Event!
​

10th NAFLD Study Group meeting 2022 (3rd Virtual)

​"Mitochondria, Biomarkers, and Treatment of NAFLD" that will take place on ZOOM on Thursday, May 12, and Friday, May 13, 16:00-19:00 CET. Please mark your calendar.
This Webinar brings together the most recent data in an exceptional program. We hope you will join us motivated by the exceptional lectures. The Q&A interactive sessions helped by your enthusiastic participation will turn this webinar into a fruitful gathering. You can see the program HERE

REGISTRATION IS OPEN

https://us02web.zoom.us/webinar/register/WN_zGn0qb_JQ4u0QvtGptp40Q
Registration is free, but pre-registration is required.
Here is the link to register in advance for this webinar.
Hope you can join!
Picture
Kick-off
​meeting 2013

Finland March 22-23, 2013

Links